ROSIGLITAZONE MALEATE by Novartis is avandamet: avandamet combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: rosiglitazone, a member of the thiazolidinedione class, and metformin, a member of the biguanide class.
Drug data last refreshed 19h ago
AVANDAMET: AVANDAMET combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: Rosiglitazone, a member of the thiazolidinedione class, and metformin, a member of the biguanide class. Thiazolidinediones are insulin sensitizing…
Worked on ROSIGLITAZONE MALEATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate